<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22945" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>HIV-1&#x02013;Associated Toxoplasmosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ayoade</surname>
            <given-names>Folusakin</given-names>
          </name>
          <aff>University of Miami</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Joel Chandranesan</surname>
            <given-names>Andrew Stevenson</given-names>
          </name>
          <aff>Louisiana State University - Shreveport</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Folusakin Ayoade declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Andrew Stevenson Joel Chandranesan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>20</day>
          <month>9</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22945.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Toxoplasmosis is a common cause of central nervous system infection in patients with HIV/AIDS who do not take appropriate prophylaxis. Cerebral toxoplasmosis typically manifests as one or more central nervous system mass lesions. Patients present with headache, confusion, and lethargy. This activity reviews the evaluation and treatment of toxoplasmosis and explains the important part played by the interprofessional team in improving care for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify&#x000a0;the pathophysiology of toxoplasmosis.</p></list-item><list-item><p>Determine the use of pyrimethamine and sulphadiazine in the treatment of toxoplasmosis.</p></list-item><list-item><p>Determine the criteria used in establishing a presumptive diagnosis of toxoplasmosis.</p></list-item><list-item><p>Communicate&#x000a0;the importance of collaboration and communication among the interprofessional team members to ensure patient compliance with highly active antiretroviral therapy medications and the use of prophylaxis to&#x000a0;prevent&#x000a0;toxoplasmosis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22945&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22945">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22945.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Toxoplasmosis is the commonest central nervous system (CNS) infection in patients with HIV/AIDS who are not on appropriate prophylaxis.&#x000a0;The usual manifestation of cerebral toxoplasmosis is typically&#x000a0;1 or more CNS mass lesions. Other opportunistic conditions seen in AIDS that may present with mass like lesions include primary CNS lymphoma (typically associated with the Epstein-Barr virus) and progressive multifocal leukoencephalopathy (PML) which is caused by JC polyomavirus.<xref ref-type="bibr" rid="article-22945.r1">[1]</xref><xref ref-type="bibr" rid="article-22945.r2">[2]</xref><xref ref-type="bibr" rid="article-22945.r3">[3]</xref></p>
      </sec>
      <sec id="article-22945.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The causative agent is&#x000a0;<italic toggle="yes">Toxoplasma&#x000a0;gondii</italic><italic toggle="yes">,</italic>&#x000a0;an exclusively intracellular, coccidian protozoan parasite with worldwide distribution. Transmission occurs following ingestion of infectious oocysts from contaminated meat, other food, or water. The oocysts are abundant in the soil, cat litter contaminated with feline feces or undercooked meat from an infected animal (especially felines). Felines are the only animals in which&#x000a0;<italic toggle="yes">T. gondii</italic>&#x000a0;can complete its reproductive cycle. After ingestion, the organisms encyst in nucleated cells and can lie dormant within the tissues for the life of the host (latent infection). In most scenarios, disease occurs following the reactivation of latent infection because of progressive loss of cellular immunity. This can occur in the setting of advanced HIV, following solid or stem cell transplant, prolonged steroids, use of monoclonal antibodies, or chemotherapy.<xref ref-type="bibr" rid="article-22945.r4">[4]</xref><xref ref-type="bibr" rid="article-22945.r5">[5]</xref></p>
      </sec>
      <sec id="article-22945.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The incidence of toxoplasmosis infection depends on the seropositivity of&#x000a0;<italic toggle="yes">Toxoplasma gondii</italic>&#x000a0;in the population. In the United States, the seropositivity of&#x000a0;<italic toggle="yes">T. gondii</italic>&#x000a0;is approximately 10% of the adult population. Seropositivity is higher in Africa and Europe, where it can reach up to 80%, and toxoplasma encephalitis could be as high as 25% to 50% of susceptible hosts. The seropositivity in the HIV population mirrors that of the general population.<xref ref-type="bibr" rid="article-22945.r6">[6]</xref><xref ref-type="bibr" rid="article-22945.r7">[7]</xref></p>
        <p>Even though cats and related felines have traditionally been associated with toxoplasmosis, the prevalence of infection is not related to owning a cat. In HIV toxoplasma-seropositive patients with CD4 less than 100 who are not on appropriate prophylaxis, the probability of developing reactivated toxoplasmosis is as high as 30%. Apart from oral transmission, toxoplasmosis can also be transmitted via the placenta from mother to fetus or through transplantation of an infected organ.</p>
      </sec>
      <sec id="article-22945.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>After ingestion of the infective forms, the organism invades the intestinal epithelium and subsequently disseminates throughout the body. At the tissues, which often is the brain but can affect any tissue, they then encyst and lie dormant until immunity wanes. The dormant forms are called bradyzoites, while the actively replicating forms are called tachyzoites. Primary toxoplasmosis is often subclinical but could rarely present symptomatically in an immunocompromised seronegative person who became recently exposed to the infective forms. In this scenario, IgM to a&#x000a0;toxoplasma is often positive, but IgG is not, unlike most reactivation cases, when IgG is the only positive serology test. As previously outlined, in most situations, clinical toxoplasmosis in the HIV patient is due to the reactivation of latent infection as immunity wanes.<xref ref-type="bibr" rid="article-22945.r8">[8]</xref></p>
      </sec>
      <sec id="article-22945.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The histology usually reveals diffuse encephalitis, cyst-containing lesions, microglial nodules, and lymphocytic vasculitis.</p>
      </sec>
      <sec id="article-22945.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Cerebral toxoplasmosis (toxoplasmic encephalitis), usually with&#x000a0;1 or more ring-enhancing brain lesions, is the typical&#x000a0;presentation in patients with HIV (see <bold>Image. </bold>Cerebral&#x000a0;Toxoplasmosis).&#x000a0;Symptoms are&#x000a0;often subacute, ranging from a few days to a month.&#x000a0;Common symptoms include a headache, confusion, and lethargy. Fever may be present but often absent.&#x000a0;There is some suggestion that a chronic toxoplasma infection state may not be completely asymptomatic, and in some patients, behavioral changes and neuropsychiatric disorders are possible. Seizures and focal neurologic deficits are also common, occurring in up to 30% and 70% of patients, respectively. Mental status changes could range from dull affect to stupor and coma, often secondary to global encephalitis or increased intracranial pressure. On the other hand, the latent or dormant phase is often asymptomatic.</p>
        <p>Extracerebral involvement is typically less common than CNS infection. These include pneumonitis and chorioretinitis, and less commonly, the gut, liver, heart, bladder, spinal cord, bone marrow, and testes. Rarely, toxoplasmosis may present as a disseminated disease.</p>
      </sec>
      <sec id="article-22945.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>There are no routine laboratory findings that are specific to toxoplasmosis. Lactate dehydrogenase (LDH) can be increased&#x000a0;markedly&#x000a0;in patients with disseminated toxoplasmosis and pulmonary disease.<xref ref-type="bibr" rid="article-22945.r2">[2]</xref><xref ref-type="bibr" rid="article-22945.r9">[9]</xref><xref ref-type="bibr" rid="article-22945.r10">[10]</xref></p>
        <p>A presumptive diagnosis of cerebral toxoplasmosis in the HIV patient can be made as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>CD4 count less than 100 cells/microliter without any effective prophylaxis</p>
          </list-item>
          <list-item>
            <p>A compatible clinical syndrome</p>
          </list-item>
          <list-item>
            <p>A positive <italic toggle="yes">T. gondii</italic>&#x000a0;immunoglobulin (Ig) G antibody (Antitoxoplasma IgM antibodies are usually absent except rarely in cases of primary infection. Quantitative IgG antibody titers are not helpful in diagnosis.)</p>
          </list-item>
          <list-item>
            <p>Brain imaging (preferably MRI) that demonstrates a typical radiographic appearance</p>
          </list-item>
        </list>
        <p>If the above criteria are present, there is at least a 90% probability the diagnosis&#x000a0;is cerebral toxoplasmosis. However, it is important to note that a positive serology does not confirm the diagnosis, and a negative serology implies the diagnosis is not likely (though not impossible) to be cerebral toxoplasmosis.</p>
        <p>Brain imaging often shows multiple (67%) or single (33%) ring-enhancing brain lesions often associated with edema. There is a predilection for involvement of the basal ganglia, corticomedullary junction, or brain white matter.</p>
        <p>A more definitive diagnosis can be made by obtaining a lumbar puncture. Cerebrospinal fluid (CSF) analysis often shows mononuclear pleocytosis, elevated protein, and, sometimes, reduced CSF glucose. Polymerase chain reaction (PCR) testing for <italic toggle="yes">T. gondii</italic> in CSF is 100% specific but only 44% to 65% sensitive. This suggests a positive CSF PCR result establishes the diagnosis of cerebral toxoplasmosis, but a negative one does not rule it out.</p>
        <p>When the diagnosis is in doubt, and alternative diagnoses are considered, a brain biopsy can be obtained. Findings in cerebral toxoplasmosis may show necrotic abscesses with blood vessel thrombosis and necrosis. Cysts containing bradyzoites may often be found coexisting with numerous active tachyzoites. In most cases, brain biopsy is not required for diagnosis.</p>
      </sec>
      <sec id="article-22945.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The treatment of toxoplasmosis in HIV-infected patients includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Antimicrobial therapy directed against <italic toggle="yes">T. gondii</italic></p>
          </list-item>
          <list-item>
            <p>Antiretroviral therapy for immune recovery</p>
          </list-item>
        </list>
        <p>Pyrimethamine and sulfadiazine are most commonly employed in treatment. Both agents synergistically and sequentially block folic acid metabolism, which is necessary to develop the parasite. Folinic acid (leucovorin) is often added to replace folate stores, which are nonselectively depleted. Initial treatment is typically for&#x000a0;6 weeks.<xref ref-type="bibr" rid="article-22945.r11">[11]</xref><xref ref-type="bibr" rid="article-22945.r12">[12]</xref><xref ref-type="bibr" rid="article-22945.r13">[13]</xref><xref ref-type="bibr" rid="article-22945.r12">[12]</xref></p>
        <p>Initial therapy is followed by secondary prophylaxis or maintenance therapy, which continues until CD4 plus T-lymphocyte counts are over 200 cells/microliters for over&#x000a0;3 months. In addition to awaiting immune recovery, secondary prophylaxis provides continuous therapy against dormant cystic forms, which may rupture and reinitiate the infectious process at any time. Maintenance therapy, therefore, is necessary to prevent relapse.</p>
        <p>In patients who are allergic to sulfonamides, treatment options include clindamycin, trimethoprim/sulfamethoxazole, pyrimethamine plus atovaquone plus folinic acid, pyrimethamine plus azithromycin plus folinic acid, and atovaquone alone (if unable to tolerate sulfur drugs or pyrimethamine). Spiramycin is the drug of choice in the first trimester of pregnancy, as pyrimethamine may be teratogenic.</p>
        <p>Most clinicians often employ the use of steroids (when edema is present), but studies have shown its use to be neither beneficial nor harmful. The use of steroids in cerebral toxoplasmosis should probably be limited to impending brain herniation as the diagnosis may be clouded once the steroid is started before a definitive diagnosis is made.</p>
        <p>The treatment course is often dramatic, with half the cases showing neurological improvement by day&#x000a0;3 and, in most cases, by day 7 of treatment commencement. If there is no significant improvement or worsening symptoms by days ten to 14 of therapy, repeat imaging and possibly brain biopsy should be considered. Persistent neurologic sequelae may remain in 37% of survivors, and the death rate at 1 year could vary from 10% to 60%.</p>
        <p>An integral part of therapy is starting antiretroviral (ART) agents as soon as feasible, usually within 2 weeks of starting antitoxoplasma therapy. Immune reconstitution inflammatory syndrome (IRIS), which can present as a paradoxical worsening of symptoms as immunity recovers, is rarer with toxoplasmosis than mycobacterial and cryptococcal infections. Even though there are no studies about the optimal timing of ART in toxoplasmosis, early ART has clear benefits and should not necessarily be delayed beyond 2 weeks.&#x000a0;<xref ref-type="bibr" rid="article-22945.r14">[14]</xref><xref ref-type="bibr" rid="article-22945.r15">[15]</xref></p>
      </sec>
      <sec id="article-22945.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnoses for HIV-1&#x02013;associated toxoplasmosis include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>CNS lymphoma</p>
          </list-item>
          <list-item>
            <p>CNS tuberculosis</p>
          </list-item>
          <list-item>
            <p>Cryptococcus</p>
          </list-item>
          <list-item>
            <p>Neurosyphilis</p>
          </list-item>
          <list-item>
            <p>Cardioembolic stroke</p>
          </list-item>
          <list-item>
            <p>Cytomegalovirus infection</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22945.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of HIV-1&#x02013;associated toxoplasmosis include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Changes in personality</p>
          </list-item>
          <list-item>
            <p>Seizures</p>
          </list-item>
          <list-item>
            <p>Cranial nerve palsy</p>
          </list-item>
          <list-item>
            <p>Hemiparesis</p>
          </list-item>
          <list-item>
            <p>Hemianopia</p>
          </list-item>
          <list-item>
            <p>Ataxia</p>
          </list-item>
          <list-item>
            <p>Aphasia</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22945.s12" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>Once antibiotic treatment has started, improvement is gradual and may take several weeks. Imaging studies need to be repeated in 4 to 6 weeks to determine if the lesion is decreasing in size. Long-term&#x000a0;therapy is continued at low doses. If the CD4 count improves and the lesion resolves, one may discontinue the therapy.</p>
      </sec>
      <sec id="article-22945.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients with&#x000a0;HIV-1&#x02013;associated toxoplasmosis should be advised to avoid eating raw or undercooked meat and wash their hands thoroughly after handling cat litter or soil</p>
      </sec>
      <sec id="article-22945.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Prophylaxis against reactivation of <italic toggle="yes">T. gondii</italic> in seropositive patients with CD4 lymphocyte counts less than 100 cells/microliter&#x000a0;is recommended. Trimethoprim/sulfamethoxazole is mostly used. Other options include dapsone plus pyrimethamine, folinic acid,<bold>&#x000a0;</bold>or atovaquone with or without pyrimethamine/leucovorin.</p>
        <p>In conclusion, toxoplasmosis should always be included in the differential diagnosis of CNS lesions in advanced HIV/AIDS. Diagnosis combines clinical symptoms and signs, serology, and imaging. CSF may further support the diagnosis. Brain biopsy is often reserved for difficult cases. Treatment is often dramatic, and most patients have a favorable clinical outcome.&#x000a0;</p>
      </sec>
      <sec id="article-22945.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The role of the interprofessional healthcare team cannot be overemphasized in the management of HIV patients with CNS toxoplasmosis.&#x000a0;Clinicians should emphasize safe sex practices and&#x000a0;provide counseling&#x000a0;on sex education. Washing hands after contact with cat litter is&#x000a0;highly recommended. In addition, walking barefeet in contaminated soil is not recommended. Patients should be cautioned against the use of intravenous drugs. One should wash hands after coming into contact with raw meat and wear gloves when gardening. Because these patients are on many medications, including HAART, pharmacists are in the ideal position to encourage compliance and oversee the regimen. Patients with HIV and CNS toxoplasmosis require lifelong prophylaxis with trimethoprim-sulfamethoxazole; pharmacists should educate patients on potential complications if therapy is not complied with. Finally, these individuals should be told to avoid travel to areas where toxoplasmosis is endemic. Only through an established, integrative, interprofessional team approach can the morbidity and mortality of CNS toxoplasmosis&#x000a0;be lowered in HIV patients.<xref ref-type="bibr" rid="article-22945.r16">[16]</xref><xref ref-type="bibr" rid="article-22945.r17">[17]</xref></p>
        <p>The prognosis of CNS toxoplasmosis in HIV is guarded. Relapses are very common if the treatment is discontinued. Ongoing treatment can lower the risk of recurrent infection. If the disorder is not treated adequately, complications like deafness, seizures, and blindness can occur. Infants with congenitally acquired toxoplasmosis&#x000a0;generally have a better outcome than HIV adults.<xref ref-type="bibr" rid="article-22945.r18">[18]</xref><xref ref-type="bibr" rid="article-22945.r19">[19]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-22945.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22945&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22945">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/hiv-1-associated-toxoplasmosis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=22945">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22945/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22945">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-22945.s17">
        <fig id="article-22945.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Cerebral Toxoplasmosis. A transverse section of T2 Brain MRI with and without contrast shows a ring-enhancing lesion with surrounding edema and minimal midline shift. Contributed by F Ayoade, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="TOXO__CNS" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-22945.s18">
        <title>References</title>
        <ref id="article-22945.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giovane</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Lavender</surname>
                <given-names>PD</given-names>
              </name>
            </person-group>
            <article-title>Central Nervous System Infections.</article-title>
            <source>Prim Care</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>45</volume>
            <issue>3</issue>
            <fpage>505</fpage>
            <page-range>505-518</page-range>
            <pub-id pub-id-type="pmid">30115337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22945.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paquet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yudin</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>No. 285-Toxoplasmosis in Pregnancy: Prevention, Screening, and Treatment.</article-title>
            <source>J Obstet Gynaecol Can</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>40</volume>
            <issue>8</issue>
            <fpage>e687</fpage>
            <page-range>e687-e693</page-range>
            <pub-id pub-id-type="pmid">30103893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22945.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mendez</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Koshy</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Toxoplasma gondii: Entry, association, and physiological influence on the central nervous system.</article-title>
            <source>PLoS Pathog</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>13</volume>
            <issue>7</issue>
            <fpage>e1006351</fpage>
            <pub-id pub-id-type="pmid">28727854</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22945.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rapalino</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Mullins</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Intracranial Infectious and Inflammatory Diseases Presenting as Neurosurgical Pathologies.</article-title>
            <source>Neurosurgery</source>
            <year>2017</year>
            <month>Jul</month>
            <day>01</day>
            <volume>81</volume>
            <issue>1</issue>
            <fpage>10</fpage>
            <page-range>10-28</page-range>
            <pub-id pub-id-type="pmid">28575459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22945.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sonneville</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Magalhaes</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Meyfroidt</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Central nervous system infections in immunocompromised patients.</article-title>
            <source>Curr Opin Crit Care</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>128</fpage>
            <page-range>128-133</page-range>
            <pub-id pub-id-type="pmid">28169858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22945.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crabtree-Ram&#x000ed;rez</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Caro-Vega</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shepherd</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Grinsztejn</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wolff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cortes</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Padgett</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Carriquiry</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Jayathilake</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Person</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>McGowan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sierra-Madero</surname>
                <given-names>J</given-names>
              </name>
              <collab>Caribbean, Central and South America Network for HIV Epidemiology (CCASAnet), of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) Program</collab>
            </person-group>
            <article-title>Time to HAART Initiation after Diagnosis and Treatment of Opportunistic Infections in Patients with AIDS in Latin America.</article-title>
            <source>PLoS One</source>
            <year>2016</year>
            <volume>11</volume>
            <issue>6</issue>
            <fpage>e0153921</fpage>
            <pub-id pub-id-type="pmid">27271083</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22945.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kishida</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>[Neurological complications with HIV infection].</article-title>
            <source>Brain Nerve</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>65</volume>
            <issue>3</issue>
            <fpage>275</fpage>
            <page-range>275-81</page-range>
            <pub-id pub-id-type="pmid">23475519</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22945.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ho</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Sheng</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Clinical presentation and outcome of toxoplasmic encephalitis in patients with human immunodeficiency virus type 1 infection.</article-title>
            <source>J Microbiol Immunol Infect</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>41</volume>
            <issue>5</issue>
            <fpage>386</fpage>
            <page-range>386-92</page-range>
            <pub-id pub-id-type="pmid">19122919</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22945.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brandsma</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bromberg</surname>
                <given-names>JEC</given-names>
              </name>
            </person-group>
            <article-title>Primary CNS lymphoma in HIV infection.</article-title>
            <source>Handb Clin Neurol</source>
            <year>2018</year>
            <volume>152</volume>
            <fpage>177</fpage>
            <page-range>177-186</page-range>
            <pub-id pub-id-type="pmid">29604975</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22945.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Christo</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Vilela</surname>
                <given-names>Mde C</given-names>
              </name>
              <name>
                <surname>Bretas</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Domingues</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Greco</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Livramento</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Teixeira</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Cerebrospinal fluid levels of chemokines in HIV infected patients with and without opportunistic infection of the central nervous system.</article-title>
            <source>J Neurol Sci</source>
            <year>2009</year>
            <month>Dec</month>
            <day>15</day>
            <volume>287</volume>
            <issue>1-2</issue>
            <fpage>79</fpage>
            <page-range>79-83</page-range>
            <pub-id pub-id-type="pmid">19782379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22945.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Okome-Nkoumou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guiyedi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ondounda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Efire</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Clevenbergh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dibo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dzeing-Ella</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Opportunistic diseases in HIV-infected patients in Gabon following the administration of highly active antiretroviral therapy: a retrospective study.</article-title>
            <source>Am J Trop Med Hyg</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>90</volume>
            <issue>2</issue>
            <fpage>211</fpage>
            <page-range>211-5</page-range>
            <pub-id pub-id-type="pmid">24323514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22945.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thoden</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Potthoff</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bogner</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Brockmeyer</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Esser</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grabmeier-Pfistershammer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>H&#x000e4;rter</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hartmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Herzmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hutterer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mauss</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Meyer-Olson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mosthaf</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Oette</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reuter</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rieger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rosenkranz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ruhnke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schaaf</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schwarze</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stellbrink</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Stocker</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Stoehr</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stoll</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tr&#x000e4;der</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vogel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wyen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hoffmann</surname>
                <given-names>C</given-names>
              </name>
              <collab>Deutsche AIDS Gesellschaft</collab>
              <collab>&#x000d6;sterreichische AIDS-Gesellschaft</collab>
            </person-group>
            <article-title>Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/&#x000d6;AG) (AWMF 055/066).</article-title>
            <source>Infection</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>41 Suppl 2</volume>
            <issue>Suppl 2</issue>
            <fpage>S91</fpage>
            <page-range>S91-115</page-range>
            <pub-id pub-id-type="pmid">24037688</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22945.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Low</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gavriilidis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Larke</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>B-Lajoie</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Drouin</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Stover</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Muhe</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Easterbrook</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Incidence of Opportunistic Infections and the Impact of Antiretroviral Therapy Among HIV-Infected Adults in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis.</article-title>
            <source>Clin Infect Dis</source>
            <year>2016</year>
            <month>Jun</month>
            <day>15</day>
            <volume>62</volume>
            <issue>12</issue>
            <fpage>1595</fpage>
            <page-range>1595-1603</page-range>
            <pub-id pub-id-type="pmid">26951573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22945.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>IL</given-names>
              </name>
              <name>
                <surname>McArthur</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>HIV-associated neurological disorders: a guide to pharmacotherapy.</article-title>
            <source>CNS Drugs</source>
            <year>2012</year>
            <month>Feb</month>
            <day>01</day>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>123</fpage>
            <page-range>123-34</page-range>
            <pub-id pub-id-type="pmid">22201342</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22945.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Masur</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>KK</given-names>
              </name>
              <collab>U.S. Public Health Service</collab>
              <collab>Infectious Diseases Society of America</collab>
            </person-group>
            <article-title>Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America.</article-title>
            <source>Ann Intern Med</source>
            <year>2002</year>
            <month>Sep</month>
            <day>03</day>
            <volume>137</volume>
            <issue>5 Pt 2</issue>
            <fpage>435</fpage>
            <page-range>435-78</page-range>
            <pub-id pub-id-type="pmid">12617574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22945.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaplan</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Masur</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>KK</given-names>
              </name>
              <collab>USPHS</collab>
              <collab>Infectious Disease Society of America</collab>
            </person-group>
            <article-title>Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America.</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2002</year>
            <month>Jun</month>
            <day>14</day>
            <volume>51</volume>
            <issue>RR-8</issue>
            <fpage>1</fpage>
            <page-range>1-52</page-range>
            <pub-id pub-id-type="pmid">12081007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22945.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kirk</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Lundgren</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gerstoft</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?</article-title>
            <source>AIDS</source>
            <year>1999</year>
            <month>Sep</month>
            <day>10</day>
            <volume>13</volume>
            <issue>13</issue>
            <fpage>1647</fpage>
            <page-range>1647-51</page-range>
            <pub-id pub-id-type="pmid">10509565</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22945.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robert-Gangneux</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Meroni</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dupont</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Botterel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>JMA</given-names>
              </name>
              <name>
                <surname>Brenier-Pinchart</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Accoceberry</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Akan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Abbate</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Boggian</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bruschi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Carratal&#x000e0;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>David</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Drgona</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Djurkovi&#x00107;-Djakovi&#x00107;</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Farinas</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Genco</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gkrania-Klotsas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Groll</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Guy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hirzel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kurt</surname>
                <given-names>&#x000d6;</given-names>
              </name>
              <name>
                <surname>Junie</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Lazzarotto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Len</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Munoz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pana</surname>
                <given-names>ZD</given-names>
              </name>
              <name>
                <surname>Roilides</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Stajner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>van Delden</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Villena</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Pelloux</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Manuel</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Toxoplasmosis in Transplant Recipients, Europe, 2010-2014.</article-title>
            <source>Emerg Infect Dis</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>24</volume>
            <issue>8</issue>
            <fpage>1497</fpage>
            <page-range>1497-1504</page-range>
            <pub-id pub-id-type="pmid">30014843</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22945.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Halonen</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Toxoplasmosis.</article-title>
            <source>Handb Clin Neurol</source>
            <year>2013</year>
            <volume>114</volume>
            <fpage>125</fpage>
            <page-range>125-45</page-range>
            <pub-id pub-id-type="pmid">23829904</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
